CytomX Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 97.6%

CytomX Therapeutics (CTMX) reported its fiscal 2025 Q2 earnings on Aug 07th, 2025. The company delivered results that exceeded expectations, driven by a dramatic 97.6% reduction in net loss and positive momentum in its key pipeline assets. CytomX also completed a $100 million financing and announced a new clinical milestone, setting a clear path for future growth.

Revenue
CytomX Therapeutics reported total revenue of $18.66 million in Q2 2025, representing a 25.7% decline from $25.11 million in the same period of 2024. The decrease was primarily due to the completion of obligations under the Bristol Myers Squibb collaboration and deprioritization of the CX-904 program under the Amgen agreement. The company also experienced a reduction in activities with Moderna due to budget constraints, contributing to the year-over-year decline in revenue.

Earnings/Net Income
CytomX Therapeutics maintained an EPS of $0.00 in Q2 2025, consistent with the prior year. However, the company made significant progress in reducing losses, narrowing its net loss to $-154,000, a 97.6% improvement compared to a net loss of $-6.53 million in Q2 2024. This marked a new record high for the company’s Q2 net income, the best performance in 11 years.

Price Action
The stock price of CytomX Therapeutics has declined across multiple time frames. During the latest trading day, shares fell by 4.55%, continuing a downward trend as the stock dropped 4.11% over the most recent full trading week and tumbled 12.50% month-to-date.

Post-Earnings Price Action Review
A strategic approach to investing in CytomX following a revenue increase quarter-over-quarter proved highly effective over the past three years. This strategy generated an overall return of 85.22%, outperforming the benchmark return of 49.71% by 35.52%. The performance was characterized by a strong compound annual growth rate (CAGR) of 23.57%, with no maximum drawdown recorded, showcasing its resilience and risk control.

CEO Commentary
Sean McCarthy, D.Phil., CEO and Chairman of CytomX, described Q2 2025 as an “exciting quarter” marked by key milestones, including positive interim data for CX-2051 in advanced colorectal cancer. The CEO highlighted the successful $100 million financing, which provides the company with a clear path to advance its development programs. McCarthy expressed optimism about the planned Q1 2026 Phase 1 data update for CX-2051 and the potential launch of a Phase 2 study in 1H 2026. He emphasized CytomX’s focus on leveraging its PROBODY platform to improve the standard of care in late-line CRC and its plans for combination studies in earlier lines of therapy in 2026.

Guidance
CytomX expects to provide a Phase 1 dose expansion update for CX-2051 in Q1 2026, with a planned Phase 2 study initiation in advanced, late-line colorectal cancer in 1H 2026. The company also anticipates combination studies in earlier lines of CRC therapy in 2026 and initial clinical data for the CX-801 combination with KEYTRUDA in advanced melanoma. CytomX expects its cash runway to extend through Q2 2027 and continues research collaborations, including preclinical work with Moderna on an mRNA-encoded masked IL-12 molecule.

Additional News
CytomX Therapeutics announced significant clinical and financial developments in its second quarter of 2025. The company shared positive interim data from the Phase 1 study of CX-2051, a first-in-class EpCAM Antibody Drug Conjugate for advanced colorectal cancer, with plans to initiate a Phase 2 study in 1H 2026. CytomX also began combination dose escalation of CX-801 with KEYTRUDA for advanced melanoma, expanding its clinical footprint. Financially, the company completed a $100 million common stock offering, ending Q2 2025 with $158.1 million in cash. Operating expenses declined significantly to $19.9 million from $33.6 million in Q2 2024. CytomX emphasized its strong financial position and progress toward advancing its pipeline, particularly with CX-2051. The company continues to collaborate with major pharma partners, including Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna, to validate its PROBODY® therapeutic platform.